Abstract:Objectives: Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment. Methods: A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it. Results: Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were "comparative safety/tolerability" (58 times), "comparative effectiveness/efficacy" (56 times), "comparative patient-perceived health/patient reported outcomes" (37 times), "disease severity" (34 times), and "unmet needs" (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were "cost of intervention" (17 times), "comparative other medical costs" (16 times), and "comparative non-medical costs" (18 times). Out of the 10 criteria (18 times) for assessing innovative value, "a novel pharmacological mechanism" was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, "system capacity and appropriate use of intervention" was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, "political/historical/cultural context" was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. "Swing weighting" and "a direct rating scale" were the most frequently used techniques in included articles. Conclusion: This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.

Incorporating Prior Data in Quantitative Benefit–Risk Assessments: Case Study of a Bayesian Method

Benefit-Risk Assessment of Medical Products Using Bayesian Multi-Criteria Augmented Decision Analysis (MCADA) for Clinical Development

A Comparison of Various Aggregation Functions in Multi-Criteria Decision Analysis for Drug Benefit-Risk Assessment

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Quantitative Risk Assessment: Developing a Bayesian Approach to Dichotomous Dose-Response Uncertainty

Quantification of Benefits for Medical Devices

Incorporating Historical Information to Improve Phase I Clinical Trials

Graphical models and Bayesian domains in risk modelling: application in microbiological risk assessment

[Multi-criteria decision analysis in clinical comprehensive evaluation of Chinese patent medicine]

Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA

Application Study of Multiple Criteria Decision Analysis in Health Technology Assessment

Bayesian Model-Averaged Benchmark Dose Analysis Via Reparameterized Quantal-Response Models

The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review

Bayesian Decision Curve Analysis With Bayesdca

Healthcare decision-making applications using multicriteria decision analysis: A scoping review

Double-quantitative multi-granularity kernel fuzzy rough sets model and its application in rheumatoid arthritis risk assessment

Analyzing quantitative performance: Bayesian estimation of 3-component mixture geometric distributions based on Kumaraswamy prior

An integration of hybrid MCDA framework to the statistical analysis of computer-based health monitoring applications

Incorporation of stochastic engineering models as prior information in Bayesian medical device trials

Probabilistic double hierarchy linguistic Maclaurin symmetric mean-MultiCriteria Border Approximation area Comparison method for multi-criteria group decision making and its application in a selection of traditional Chinese medicine prescriptions

Bayesian benchmark dose risk assessment with mixed‐factor quantal data